ofloxacin has been researched along with Carcinoma, Transitional Cell in 6 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized, double-blind, multicenter study 115 patients with primary or recurrent superficial bladder cancer (Ta/T1, CIS, G1-G3) and no prior bacillus Calmette-Guerin treatment were randomized to induction treatment with intravesical bacillus Calmette-Guerin (6 plus 3 instillations) plus 200 mg ofloxacin in group 1 or plus placebo in group 2." | 9.12 | The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. ( Chopin, D; Colombel, M; Malavaud, B; Nicolas, L; Rischmann, P; Saint, F, 2006) |
| "In this randomized, double-blind, multicenter study 115 patients with primary or recurrent superficial bladder cancer (Ta/T1, CIS, G1-G3) and no prior bacillus Calmette-Guerin treatment were randomized to induction treatment with intravesical bacillus Calmette-Guerin (6 plus 3 instillations) plus 200 mg ofloxacin in group 1 or plus placebo in group 2." | 5.12 | The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. ( Chopin, D; Colombel, M; Malavaud, B; Nicolas, L; Rischmann, P; Saint, F, 2006) |
| "Ciprofloxacin and ofloxacin inhibit proliferation and DNA synthesis of these 3 human TCC lines in vitro." | 1.29 | Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. ( Dixon, PS; Peretsman, SJ; Seay, TM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calleris, G | 1 |
| Marra, G | 1 |
| Corcione, S | 1 |
| Oderda, M | 1 |
| Cardellino, C | 1 |
| Audagnotto, S | 1 |
| Frea, B | 1 |
| De Rosa, FG | 1 |
| Gontero, P | 1 |
| Colombel, M | 2 |
| Picard, A | 1 |
| Saint, F | 1 |
| Chopin, D | 1 |
| Malavaud, B | 1 |
| Nicolas, L | 1 |
| Rischmann, P | 1 |
| Seay, TM | 1 |
| Peretsman, SJ | 1 |
| Dixon, PS | 1 |
| Yamakuchi, M | 1 |
| Nakata, M | 1 |
| Kawahara, K | 1 |
| Kitajima, I | 1 |
| Maruyama, I | 1 |
| Kamat, AM | 1 |
| DeHaven, JI | 1 |
| Lamm, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms With Prophylactic Pentosan Polysulphate in Patients With Non-Muscle-Invasive Bladder Cancer: A Randomized Controlled Trial[NCT03549650] | Phase 2 | 3 participants (Actual) | Interventional | 2019-05-03 | Terminated (stopped due to Given the updated precautions on Elmiron as well as the risk benefit profile, we have decided to terminate the study.) | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ofloxacin and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
[Prevention of Bacillus Calmette-Guérin immunotherapy complications].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Anti-Bacterial Agents; BCG Vaccine; Carc | 2008 |
1 trial available for ofloxacin and Carcinoma, Transitional Cell
4 other studies available for ofloxacin and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Miliary pulmonary infection after BCG intravesical instillation: a rare, misdiagnosed and mistreated complication.
Topics: Aged; Antitubercular Agents; BCG Vaccine; Bronchoalveolar Lavage Fluid; Carcinoma, Transitional Cell | 2017 |
Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics.
Topics: Anti-Infective Agents; Carcinoma, Transitional Cell; Cell Division; Ciprofloxacin; Dose-Response Rel | 1996 |
New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines.
Topics: Anti-Infective Agents; Bromodeoxyuridine; Carcinoma, Transitional Cell; Cell Cycle; DNA, Neoplasm; H | 1997 |
Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer.
Topics: Anti-Infective Agents; Antineoplastic Agents; Carcinoma, Transitional Cell; Ciprofloxacin; Dose-Resp | 1999 |